Clinical pharmacokinetics of second generation antisense oligonucleotides

Author： Yu Rosie Z   Grundy John S   Geary Richard S  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.2, 2013-02, pp. : 169-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma

By Ball H.A.   Sandrasagra A.   Tang L.   Van Scott M.   Wild J.   Nyce J.W.  

American Journal of PharmacoGenomics, Vol. 3, Iss. 2, 2003-01 ,pp. : 97-106

Adis International

Access to resources Recommend Favorite

Clinical trials of a new class of therapeutic agents: antisense oligonucleotides

By Galderisi U.   Cipollaro M.   Cascino A.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 69-79

Informa Healthcare

Access to resources Recommend Favorite

Cellular delivery of antisense oligonucleotides

By Lebedeva I.   Benimetskaya L.   Stein C.A.   Vilenchik M.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 101-119

Elsevier

Access to resources Recommend Favorite

Antisense oligonucleotides as emerging drugs

By Nyce J.W.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 365-376

Informa Healthcare

Access to resources Recommend Favorite

Antisense Oligonucleotides As Therapeutic Agents

By Alama A.   Barbieri F.   Cagnoli M.   Schettini G.  

Pharmacological Research, Vol. 36, Iss. 3, 1997-09 ,pp. : 171-178

Academic Press

Access to resources Recommend Favorite